ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Long-Term Drug-Free Survival of Tiny Cynomolgus Islet Allografts.

M. Koulmanda, V. Chipashivili, M. Duggan, T. Strom.

Surgery and Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Surgery, Massachusetts General Hospital, Boston, MA

Meeting: 2017 American Transplant Congress

Abstract number: 512

Keywords: Co-stimulation, Immunosuppression, Islets, Tolerance

Session Information

Date: Tuesday, May 2, 2017

Session Name: Concurrent Session: Islet Transplant

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:06pm-5:18pm

Location: E352

Related Abstracts
  • Survival of Free and Encapsulated Islet Xenografts Transplanted in the Mouse Bone Marrow, The
  • Implementation of a Simplified Method of Islet Isolation To Facilitate Allogeneic Islet Transplantation in Cynomolgus Monkeys

Following upon highly beneficial effects observed with short-term alpha 1-antitrypsin (AAT) treatment in the marginally sized autologous cynomolgus islet transplant model, we are testing the hypothesis that short-term peri-transplant treatment with AAT, an acute phase protein with cytoprotective, anti-inflammatory and anti-thrombotic effects, will synergize with regimens that exert potentially tolerizing effects upon T-cells. We transplanted marginally sized (4,500 -7,700IEQ/kg) allogeneic islets, into recipients treated with a co-stimulation blockade-based protocol (anti-CD40mAb (2C10R4) 50mg/kg i.v D-0,14,28,60,90,120 +RPM 0.5mg/kg-0.1mg/kg i.m D-0-120) +/- AAT (60mg/kg i.v. D-1, 3, 7, 10). In the second set of experiments we cultured islets in AAT overnight and transplanted very marginally sized (3,000-4,000IEQ/kg) islets into MHC mismatched recipients treated with anti-CD40mAb+ RPM. Results: AAT given as an adjunct to anti-CD40mAb+RPM is effective and safe in NHP recipients of islet transplants. Results in terms of transplant function are far superior to that obtained anti-CD40mAb+RPM alone. In 5 NHPs transplanted without AAT, graft survival was 169-217 days despite cessation of treatment at day 120 post-transplant. In 5 NHP recipients of marginally sized islet transplants receiving AAT as an adjunct, the graft functioned without need for insulin treatment 193-310 days post-transplant. In the second set of experiments, 3 NHPs were transplanted with exceptionally small islet allografts (3,000-4,000IEQ/kg). The islets were cultured with AAT and transplanted into recipients treated with anti-CD40mAb+RPM. In the absence of insulin treatment, the recipients quickly became and remain normoglycemic for over 200 days post-transplant. These results are without precedent. Conclusions: These results demonstrate that adjunctive AAT given with an anti-CD40mAb based regimen is efficacious in the NHP islet allograft model: (1) by blocking inflammation and treating recipients with a brief dose of AAT marginally sized islets functioned well for almost a year without the need of insulin injections despite cessation of treatment at day 120. (2) substitution of in vivo AAT treatment with culture of islets for 18hrs with AAT promoted immediate and long-term function of tiny islet allografts. Transplantation of only 3,000 IEQ/kg can be used to achieve immunosuppressive drug-free insulin independence in NHPs for prolonged period.

CITATION INFORMATION: Koulmanda M, Chipashivili V, Duggan M, Strom T. Long-Term Drug-Free Survival of Tiny Cynomolgus Islet Allografts. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Koulmanda M, Chipashivili V, Duggan M, Strom T. Long-Term Drug-Free Survival of Tiny Cynomolgus Islet Allografts. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-drug-free-survival-of-tiny-cynomolgus-islet-allografts/. Accessed January 23, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.